HSBC downgraded Biogen (BIIB) to Hold from Buy with a price target of $118, down from $342. The firm cites the company’s negative pipeline updates combined with a weaker outlook in the near term for the downgrade. Biogen’s Alzheimer’s’ adoption has been slower than expected, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Hold Rating: Challenges and Uncertainties Impacting Growth Prospects
- Strategic Collaborations and Financial Adjustments Bolster Biogen’s Growth Potential: A Buy Rating Justified
- Biogen’s Strategic Focus and Market Positioning Justify Hold Rating Amid Uncertainties
- Biogen’s Mixed Financial Outlook: Strong Leqembi Sales Amidst Challenges in MS Franchise and Skyclarys
- Biogen’s Hold Rating Amidst Restrictive EU Approval for Leqembi and Potential Stock Impact